Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04524663 · ClinicalTrials.gov registry record · Phase 2
Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT04524663: Completed Phase 2 study, sponsored by Stanford University.
NCT04524663 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04524663, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease. Patients will attend 4 study visits over a period of up to 28 days.
Interventions
- DRUG Placebo
- OTHER Standard of Care Treatment
- DRUG Camostat Mesilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-12-19 |
| Est. Completion | 2021-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524663
The ClinicalTrials.gov registry entry for NCT04524663 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04524663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04524663 about?
NCT04524663 is a clinical study titled "Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients". This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease. Patients will attend 4 study visits over a period of up to 28 days.
What is the current status of trial NCT04524663?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2020-12-19. Estimated completion is 2021-05-15.
What interventions are being tested in trial NCT04524663?
The interventions under investigation include: Placebo (DRUG), Standard of Care Treatment (OTHER), Camostat Mesilate (DRUG).
Who is sponsoring clinical trial NCT04524663?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.